204 related articles for article (PubMed ID: 28451831)
41. 64Cu-labeled folate-conjugated shell cross-linked nanoparticles for tumor imaging and radiotherapy: synthesis, radiolabeling, and biologic evaluation.
Rossin R; Pan D; Qi K; Turner JL; Sun X; Wooley KL; Welch MJ
J Nucl Med; 2005 Jul; 46(7):1210-8. PubMed ID: 16000291
[TBL] [Abstract][Full Text] [Related]
42. EC-145, a folate-targeted Vinca alkaloid conjugate for the potential treatment of folate receptor-expressing cancers.
Dosio F; Milla P; Cattel L
Curr Opin Investig Drugs; 2010 Dec; 11(12):1424-33. PubMed ID: 21154124
[TBL] [Abstract][Full Text] [Related]
43. Design, synthesis and biological evaluation of a highly-potent and cancer cell selective folate-taxoid conjugate.
Seitz JD; Vineberg JG; Herlihy E; Park B; Melief E; Ojima I
Bioorg Med Chem; 2015 May; 23(9):2187-94. PubMed ID: 25819334
[TBL] [Abstract][Full Text] [Related]
44. An Integrative Folate-Based Metal Complex Nanotube as a Potent Antitumor Nanomedicine as Well as an Efficient Tumor-Targeted Drug Carrier.
Liu LX; Li BX; Wang QY; Dong ZP; Li HM; Jin QM; Hong H; Zhang J; Wang Y
Bioconjug Chem; 2016 Dec; 27(12):2863-2873. PubMed ID: 27802029
[TBL] [Abstract][Full Text] [Related]
45. Preclinical evaluation of isostructural Tc-99m- and Re-188-folate-Gly-Gly-Cys-Glu for folate receptor-positive tumor targeting.
Kim WH; Kim CG; Kim MH; Kim DW; Park CR; Park JY; Lee YS; Youn H; Kang KW; Jeong JM; Chung JK
Ann Nucl Med; 2016 Jun; 30(5):369-79. PubMed ID: 26993818
[TBL] [Abstract][Full Text] [Related]
46. Increase of doxorubicin sensitivity for folate receptor positive cells when given as the prodrug N-(phenylacetyl) doxorubicin in combination with folate-conjugated PGA.
Zhang Q; Xiang G; Zhang Y; Yang K; Fan W; Lin J; Zeng F; Wu J
J Pharm Sci; 2006 Oct; 95(10):2266-75. PubMed ID: 16883559
[TBL] [Abstract][Full Text] [Related]
47. A dendritic β-galactosidase-responsive folate-monomethylauristatin E conjugate.
Alsarraf J; Péraudeau E; Poinot P; Tranoy-Opalinski I; Clarhaut J; Renoux B; Papot S
Chem Commun (Camb); 2015 Nov; 51(87):15792-5. PubMed ID: 26365722
[TBL] [Abstract][Full Text] [Related]
48. Conjugates of folate and anti-T-cell-receptor antibodies specifically target folate-receptor-positive tumor cells for lysis.
Kranz DM; Patrick TA; Brigle KE; Spinella MJ; Roy EJ
Proc Natl Acad Sci U S A; 1995 Sep; 92(20):9057-61. PubMed ID: 7568072
[TBL] [Abstract][Full Text] [Related]
49. Rational combination therapy of vintafolide (EC145) with commonly used chemotherapeutic drugs.
Reddy JA; Dorton R; Bloomfield A; Nelson M; Vetzel M; Guan J; Leamon CP
Clin Cancer Res; 2014 Apr; 20(8):2104-14. PubMed ID: 24429878
[TBL] [Abstract][Full Text] [Related]
50. The folate receptor as a rational therapeutic target for personalized cancer treatment.
Assaraf YG; Leamon CP; Reddy JA
Drug Resist Updat; 2014; 17(4-6):89-95. PubMed ID: 25457975
[TBL] [Abstract][Full Text] [Related]
51. Targeted tumor theranostics using folate-conjugated and camptothecin-loaded acoustic nanodroplets in a mouse xenograft model.
Chen WT; Kang ST; Lin JL; Wang CH; Chen RC; Yeh CK
Biomaterials; 2015; 53():699-708. PubMed ID: 25890765
[TBL] [Abstract][Full Text] [Related]
52. Design and synthesis of [111In]DTPA-folate for use as a tumor-targeted radiopharmaceutical.
Wang S; Luo J; Lantrip DA; Waters DJ; Mathias CJ; Green MA; Fuchs PL; Low PS
Bioconjug Chem; 1997; 8(5):673-9. PubMed ID: 9327130
[TBL] [Abstract][Full Text] [Related]
53. Folate-modified poly(2-ethyl-2-oxazoline) as hydrophilic corona in polymeric micelles for enhanced intracellular doxorubicin delivery.
Qiu LY; Yan L; Zhang L; Jin YM; Zhao QH
Int J Pharm; 2013 Nov; 456(2):315-24. PubMed ID: 24016742
[TBL] [Abstract][Full Text] [Related]
54. Radioiodinated folic acid conjugates: evaluation of a valuable concept to improve tumor-to-background contrast.
Reber J; Struthers H; Betzel T; Hohn A; Schibli R; Müller C
Mol Pharm; 2012 May; 9(5):1213-21. PubMed ID: 22509996
[TBL] [Abstract][Full Text] [Related]
55. A comparative study of folate receptor-targeted doxorubicin delivery systems: dosing regimens and therapeutic index.
Scomparin A; Salmaso S; Eldar-Boock A; Ben-Shushan D; Ferber S; Tiram G; Shmeeda H; Landa-Rouben N; Leor J; Caliceti P; Gabizon A; Satchi-Fainaro R
J Control Release; 2015 Jun; 208():106-20. PubMed ID: 25869964
[TBL] [Abstract][Full Text] [Related]
56. Targeting of pegylated liposomal mitomycin-C prodrug to the folate receptor of cancer cells: Intracellular activation and enhanced cytotoxicity.
Patil Y; Amitay Y; Ohana P; Shmeeda H; Gabizon A
J Control Release; 2016 Mar; 225():87-95. PubMed ID: 26809007
[TBL] [Abstract][Full Text] [Related]
57. Fluorine-18 click radiosynthesis and preclinical evaluation of a new 18F-labeled folic acid derivative.
Ross TL; Honer M; Lam PY; Mindt TL; Groehn V; Schibli R; Schubiger PA; Ametamey SM
Bioconjug Chem; 2008 Dec; 19(12):2462-70. PubMed ID: 19053298
[TBL] [Abstract][Full Text] [Related]
58. First total synthesis of tubulysin B.
Pando O; Dörner S; Preusentanz R; Denkert A; Porzel A; Richter W; Wessjohann L
Org Lett; 2009 Dec; 11(24):5567-9. PubMed ID: 19919080
[TBL] [Abstract][Full Text] [Related]
59. Characterization of in vivo disulfide-reduction mediated drug release in mouse kidneys.
Yang JJ; Kularatne SA; Chen X; Low PS; Wang E
Mol Pharm; 2012 Feb; 9(2):310-7. PubMed ID: 22171616
[TBL] [Abstract][Full Text] [Related]
60. Total synthesis of tubulysin U and its C-4 epimer.
Yang XD; Dong CM; Chen J; Ding YH; Liu Q; Ma XY; Zhang Q; Chen Y
Chem Asian J; 2013 Jun; 8(6):1213-22. PubMed ID: 23576385
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
